Precision Medicine Global Congress 2026 Europe

London, United Kingdom | Thursday 14th - Friday 15th May 2026

Exploring the clinical readiness of advanced therapies for mainstream adoption and the factors defining clinical maturity
Evaluating whether regulatory frameworks can keep pace with programmable medicine.
Determining if healthcare infrastructure is sufficiently prepared.
Discussing how to balance speed with safety.
Defining what responsible innovation looks like in 2026 and beyond

Analysis of clinical data currently emerging from CRISPR, base editing, and prime editing trials
Practical considerations regarding in vivo versus ex vivo delivery methods
Essential frameworks and registries required for long-term safety monitoring.
Regulatory pathways for first-in-class editing therapies
How health systems can best prepare for the implementation of curative genomic interventions.

Expansion of CAR-T into autoimmune and rare conditions
Development of allogeneic and off-the-shelf platforms to improve scalability.
Operational challenges of managing toxicity and long-term follow-up requirements
Strategies for manufacturing and turnaround optimization
Significant reimbursement implications associated with these curative cell therapies.

Expanding the application of mRNA technologies into broader therapeutic areas.
Exploring innovative technologies for precise genetic adjustments and modulation.
Improving tissue targeting and the efficiency of delivery mechanisms.
Navigating the evolving regulatory landscape for novel RNA modalities.
Refining models for expedited development to ensure effective global deployment.

Combining genomics, imaging, wearables, and EHR data
Development of more robust clinical decision support tools
Application of digital twin modeling for treatment optimization
Rigorous algorithm validation and transparency to support innovations
Addressing the complexities of maintaining continuous learning systems within strictly regulated environments.

13:00 - NETWORKING LUNCH

Implementing advanced technologies within GMP environments to enhance efficiency.
Strategies to lower the cost of goods for personalized treatments.
Ensuring a stable supply of viral vectors and essential raw materials.
Establishing localized facilities to improve global access to therapies.
Standardizing compliance across international manufacturing sites.

Establishing standards for specialized treatment center accreditation
Developing comprehensive workforce training programs tailored for the delivery of gene and cell therapies.
Prioritizing the implementation of registries for long-term patient monitoring to track longitudinal outcomes accurately
Integrating genomic testing directly into hospital systems
Improving cross-institutional care coordination will also be vital to ensuring seamless patient transitions and high-quality care

Identifying critical barriers to equitable healthcare and identify actionable strategies for more inclusive innovation
Addressing the significant gaps within genomic and clinical trial datasets to ensure therapies are effective for diverse populations.
Developing robust technology transfer models specifically tailored for low- and middle-income countries.
Facilitating public–private partnerships to ensure the equitable deployment of advanced treatments.
Establishing ethical allocation frameworks for scarce therapies and exploring policy-driven incentives to foster inclusive innovation.